GeoVax Labs 2025 Q2 Earnings EPS Narrows 82.4% Despite 6% Increase in Net Loss

GeoVax Labs (GOVX) reported fiscal 2025 Q2 earnings on November 14, 2025, showing an 82.4% improvement in per-share losses to -$0.35 but a 6% wider net loss to -$5.37 million. The company emphasized progress in vaccine and oncology programs, though revenue growth outpaced profitability.

Revenue

GeoVax Labs reported total revenue of $852,282 in Q2 2025, driven entirely by government contract revenue, a 183.5% increase from $300,677 in the same period last year.

Earnings/Net Income

The company narrowed losses to $0.35 per share in Q2 2025 from $1.99 in Q2 2024, an 82.4% improvement. However, the net loss widened to $5.37 million from $5.06 million, reflecting ongoing financial challenges. The EPS improvement was offset by a wider net loss, highlighting mixed performance despite progress in key programs.

Price Action

The stock price rose 5.00% on the latest trading day but fell 12.17% for the week and 24.40% month-to-date.

Post-Earnings Price Action Review

The strategy of buying GOVX shares on revenue raise announcements and holding for 30 days showed mixed performance over three years. While yielding a 20% total return—slightly outperforming SPY’s 15%—quarterly returns were volatile, with +25% in Q1 2023 and -15% in Q2 2023. Consistency remained elusive, influenced by market conditions and company-specific developments. Investors must weigh risk tolerance against potential volatility.

CEO Commentary

CEO David Dodd highlighted progress in GEO-MVA, GEO-CM04S1, and Gedeptin, emphasizing expedited regulatory pathways and global partnerships. Strategic priorities include addressing immunocompromised populations and advancing oncology programs.

Guidance

The CEO outlined qualitative milestones, including advancing GEO-MVA to clinical evaluation in 2026 and prioritizing partnerships for global commercialization. No quantitative targets were provided.

Additional News

1. Q3 Earnings Disappointment: GeoVax’s Q3 2025 GAAP EPS of -$0.31 missed estimates by $0.04, with revenue dropping to $2.5 million from $3.1 million in Q3 2024 due to BARDA contract termination.

2. Strategic Collaborations: The company intensified discussions with global stakeholders, including the White House, WHO, and Africa CDC, to secure partnerships for GEO-MVA and CM04S1.

3. Manufacturing Advancements: GeoVax partnered with Oxford Biomedica for MVA vaccine production and explored needle-free delivery via Vaxxas’ microarray patch technology.

[Insert image of GeoVax’s vaccine development pipeline here]